Leap Therapeutics (LPTX) Receives Coverage Optimism Score of 0.09

News coverage about Leap Therapeutics (NASDAQ:LPTX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.1092650867404 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several equities research analysts recently issued reports on LPTX shares. ValuEngine upgraded Leap Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, March 22nd. HC Wainwright started coverage on Leap Therapeutics in a report on Thursday, April 12th. They set a “buy” rating and a $12.50 price target for the company. Finally, Zacks Investment Research downgraded Leap Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 17th.

Leap Therapeutics traded up $0.23, hitting $8.68, during trading on Wednesday, MarketBeat.com reports. 300 shares of the company were exchanged, compared to its average volume of 58,579. Leap Therapeutics has a 52 week low of $4.90 and a 52 week high of $10.25. The company has a market capitalization of $122.24 million, a P/E ratio of -2.62 and a beta of 0.35.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings results on Friday, May 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.24). sell-side analysts anticipate that Leap Therapeutics will post -2.23 EPS for the current fiscal year.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply